Cefaclor Price Trend and Forecast 2026: Latest Global Market Analysis and Industry Outlook

 

Acoording to ChemAnalyst, the global Cefaclor Price market recorded mixed regional movement during the second quarter of 2026. Prices declined in the USA, China, and Germany, while India recorded an increase. In June 2026, Cefaclor prices stood at approximately USD 212,155/MT in the USA, USD 212,020/MT in China, USD 205,074.68/MT in India, and USD 212,150/MT in Germany.

During Q2 2026, the USA Cefaclor Price Index declined by 6.75% quarter-over-quarter, while China recorded a 6.76% QoQ decline. Germany also experienced a 6.75% QoQ decrease, whereas India's Cefaclor Price Index increased by 4.59% QoQ. The regional differences reflected variations in import availability, export supply, inventories, freight costs, procurement activity, and local purchasing conditions.

Cefaclor is a pharmaceutical active ingredient used in oral antibiotic formulations. Consequently, its pricing is influenced not only by chemical production costs but also by pharmaceutical procurement, regulatory requirements, compliant API availability, hospital tenders, inventories, and international trade flows.

Cefaclor Prices in North America

In the United States, the Cefaclor Price Index declined by 6.75% QoQ during Q2 2026. The average price for the quarter was approximately USD 212,560.67/MT. Increased availability from Chinese and Indian suppliers contributed to greater landed supply and put downward pressure on market offers.

The market experienced an unusual combination of higher logistics costs and weaker spot pricing. Container freight and insurance expenses increased during the quarter, raising landed costs for importers. However, these additional expenses were partly offset by greater Asian export availability and currency movements, preventing the increase in logistics costs from translating directly into higher Cefaclor prices.

Summer demand was also relatively subdued. Hospitals delayed some tenders, while wholesalers relied on existing inventories. Stock levels remained around four to five weeks, reducing the urgency for immediate purchases and limiting seller pricing power.

The Cefaclor Price Trend in the USA therefore remained closely connected to import availability, compliant API supply, freight rates, hospital procurement, wholesaler inventories, and seasonal demand.

Cefaclor Prices in Asia-Pacific

China experienced a 6.76% quarter-over-quarter decline in the Cefaclor Price Index during Q2 2026. The average price was approximately USD 212,423.33/MT. Ample domestic supply, increased coastal inventories, and weaker export enquiries encouraged suppliers to reduce FOB offers.

Major Chinese producers continued operating close to nameplate capacity, keeping finished Cefaclor supply relatively abundant. Higher operating rates reduced the possibility of a significant supply shortage and increased competition among exporters.

Another important factor was the availability of 7-ACA feedstock, a key intermediate associated with cephalosporin production. Stable feedstock availability and relatively flat coal-derived steam costs helped keep production expenses under control.

At the same time, domestic volume-based procurement and inventory drawdowns in overseas markets weakened immediate API demand. Exporters therefore had limited pricing leverage and offered concessions to secure orders.

India moved in the opposite direction. Its Cefaclor Price Index increased by 4.59% QoQ, reflecting higher landed costs. However, spot prices softened in June as state tenders moderated purchases and private pharmaceutical formulators postponed some orders.

Cefaclor Prices in Europe

Germany recorded a 6.75% QoQ decline in the Cefaclor Price Index during Q2 2026. The average price was approximately USD 212,557.33/MT. Greater availability from Asian suppliers, particularly China and India, increased competition among importers and placed downward pressure on German market prices.

Zhejiang and Andhra suppliers discounted shipments to reduce port-side inventories, providing European buyers with additional sourcing options. Adequate container availability and inventory accumulation at Hamburg further strengthened buyer negotiating power.

Despite elevated energy costs, energy represented only a limited portion of the overall Cefaclor cost structure. Consequently, higher production expenses were insufficient to offset the downward pressure created by greater Asian availability.

German demand also remained relatively subdued. Paediatric suspension demand remained stable, but reimbursement pressures and healthcare cost controls limited the ability of formulators to accept higher procurement prices.

The European Cefaclor Price Trend will therefore continue to depend on Asian export availability, currency movements, European inventories, freight costs, reimbursement conditions, and pharmaceutical procurement.

𝐓𝐫𝐚𝐜𝐤 𝐑𝐞𝐚𝐥-𝐓𝐢𝐦𝐞 𝐏𝐫𝐢𝐜𝐞𝐬 𝐨𝐟 𝐂𝐞𝐟𝐚𝐜𝐥𝐨𝐫

https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Cefaclor

Key Factors Influencing the Cefaclor Price Trend

Several supply-side and demand-side factors are expected to shape the Cefaclor Price Trend throughout 2026.

1. 7-ACA Feedstock Availability

7-ACA availability is an important factor for Cefaclor manufacturing economics. Stable availability can limit production-cost inflation, while shortages or higher feedstock prices can increase API manufacturing expenses.

During Q2 2026, China benefited from relatively stable 7-ACA availability, helping producers maintain production economics and limiting cost-driven price increases.

2. Pharmaceutical Demand

Cefaclor demand is linked to pharmaceutical formulation and antibiotic procurement. Hospital tenders, paediatric prescriptions, private pharmaceutical production, and distributor restocking can significantly affect short-term purchasing activity.

During Q2, summer demand was relatively muted in the USA, while procurement conditions in China and Germany also limited stronger price recovery.

3. Import and Export Availability

International trade plays an important role because several major pharmaceutical markets depend on imported API supply. Increased exports from China and India expanded availability in North America and Europe during Q2 2026.

Greater Asian supply contributed to lower prices in the USA and Germany, demonstrating the importance of global sourcing patterns in determining regional Cefaclor prices.

4. Freight and Insurance Costs

Cefaclor is traded internationally, making shipping costs an important component of landed pricing. Container freight spikes and higher insurance expenses increased procurement costs during Q2.

However, greater product availability and supplier competition offset much of this logistics pressure in several markets.

5. Inventory Levels

Inventory levels influence purchasing urgency and supplier negotiating power. When pharmaceutical manufacturers and wholesalers hold sufficient stock, they can postpone procurement and negotiate lower prices.

In the USA, four to five weeks of inventory reduced immediate buying pressure during Q2. In China, higher coastal inventories also encouraged sellers to offer more competitive prices.

6. Regulatory and Quality Compliance

Pharmaceutical APIs must meet strict quality and regulatory requirements. Quality audits, retesting, GMP compliance, and certification requirements can affect the availability of compliant material.

Earlier in 2026, selective quality retesting of 7-ACA intermediates in the USA reduced compliant spot availability and contributed to higher Q1 pricing. Chinese environmental inspections also temporarily restricted exports to Europe during Q1.

Historical Cefaclor Price Movement in 2026

The first half of 2026 demonstrated how quickly the Cefaclor market can shift between supply tightness and surplus conditions.

During Q1 2026, the USA recorded a 4.117% QoQ increase, with the average price reaching approximately USD 227,947/MT. China increased by 4.11% QoQ, averaging around USD 227,830/MT FOB Shanghai, while Germany increased by 4.13% QoQ, reaching approximately USD 227,955/MT.

The Q1 increases were associated with tighter compliant supply, higher freight costs, reduced inventories, quality retesting, environmental inspections, and stronger forward procurement.

The situation changed in Q2 as Asian supply availability improved. Greater Chinese and Indian exports increased supply in North America and Europe, while weaker procurement activity reduced demand pressure. This resulted in substantial quarter-over-quarter declines in the USA, China, and Germany.

India was an exception, with its Q2 index increasing by 4.59% because of higher landed costs.

Cefaclor Product Characteristics and Applications

Cefaclor is an oral cephalosporin antibiotic used to treat bacterial infections caused by susceptible microorganisms. It works by inhibiting bacterial cell-wall synthesis, ultimately weakening the bacterial cell and causing its death.

The API is used in pharmaceutical formulations for conditions including respiratory tract infections, urinary tract infections, skin infections, and ear infections. It is commonly supplied in oral dosage forms such as capsules, tablets, and suspensions.

According to ChemAnalyst, the product is traded as pharmaceutical-grade material under CAS No. 53994-73-3 and HS Code 29419090. The listed contract size is 25 kg, with drum packaging and GMP/cGMP-approved manufacturing facilities.

The pharmaceutical nature of Cefaclor means that price competition cannot be considered separately from product quality, regulatory compliance, certification, and supplier qualification.

Cefaclor Production Cost Outlook

Production costs are expected to remain an important component of the Cefaclor Price Trend during the remainder of 2026.

Feedstock prices, utilities, coal-derived steam costs, energy, quality testing, compliance expenses, packaging, and logistics can all influence producer margins. Stable 7-ACA availability and efficient plant operations may limit cost increases, while unexpected plant disruptions or regulatory inspections could tighten supply.

The balance between production efficiency and pharmaceutical compliance requirements will remain particularly important for producers competing in export markets.

Cefaclor Demand Outlook for 2026

The demand outlook for Cefaclor is expected to remain relatively stable but regionally differentiated.

Routine pharmaceutical procurement and paediatric prescriptions provide a baseline level of demand. However, hospital tender timing, reimbursement restrictions, distributor inventories, and seasonal purchasing patterns can create short-term fluctuations.

In the USA, summer demand remained muted during Q2, while German demand was restrained by reimbursement pressure. China experienced weaker domestic and export enquiries during the quarter.

Any improvement in hospital procurement, distributor restocking, or export demand could provide support to prices later in 2026.

Cefaclor Price Forecast 2026

The Cefaclor Price Forecast for 2026 points toward a market characterized by moderate volatility rather than a sustained one-directional movement.

After the strong increases recorded during Q1, prices corrected in several major markets during Q2 as Asian supply became more available. The USA, China, and Germany are likely to remain sensitive to export volumes, inventories, freight rates, and pharmaceutical procurement.

China may continue to experience competitive pricing if producers maintain high operating rates and exportable inventories remain comfortable. In North America and Europe, greater Asian availability could continue to limit upward price movements unless logistics disruptions or supply restrictions emerge.

India may show different pricing behavior because domestic tenders, private pharmaceutical procurement, and landed import costs can influence the market independently of international FOB conditions.

The outlook could become firmer if compliant API availability tightens, freight costs rise significantly, 7-ACA feedstock becomes more expensive, or pharmaceutical manufacturers rebuild inventories.

Conversely, sustained high production rates, ample inventories, weaker export enquiries, and subdued procurement could keep prices under pressure.

Conclusion

The 2026 Cefaclor Price Trend demonstrates the importance of supply availability, pharmaceutical procurement, feedstock costs, inventories, and international logistics in determining regional market conditions.

Q2 2026 saw the USA, China, and Germany record declines of around 6.75% QoQ, while India registered a 4.59% increase. The contrasting movements were largely caused by differences in landed costs, export availability, inventories, domestic procurement, and supplier competition.

Looking ahead, 7-ACA availability, production rates, regulatory compliance, hospital tenders, pharmaceutical demand, freight costs, inventories, and China and India export flows will remain key indicators for buyers and suppliers monitoring the Cefaclor Price market.

For procurement teams, pharmaceutical manufacturers, distributors, and traders, tracking these factors can provide a clearer understanding of potential price movements and help support more informed sourcing decisions. ChemAnalyst provides ongoing price assessments, market intelligence, demand-supply insights, and forecasts for pharmaceutical APIs and other global commodities.

Contact Us:

Address:

420 Lexington Avenue, Suite 300 New York, NY 10170 United States

Phone: +1 332 258 6602

Email: sales@chemanalyst.com

Website: https://www.chemanalyst.com/

LinkedIn: https://www.linkedin.com/company/chemanalyst/

Facebook: https://www.facebook.com/ChemAnalysts/

Twitter: https://x.com/chemanalysts

YouTube: https://www.youtube.com/@chemanalyst

Instagram: https://www.instagram.com/chemanalyst_